Could a heart pill protect kidneys in new dialysis patients?
NCT ID NCT05498181
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested a drug called sacubitril/valsartan (a heart failure medication) in 45 adults who had just started hemodialysis. The goal was to see if it could improve heart function and help preserve any remaining kidney function compared to a placebo. Participants took the drug or placebo for 16 weeks while continuing their regular dialysis.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEMODIALYSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Brigham and Women's
Boston, Massachusetts, 02115, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can video games and electric pulses ease dialysis Patients' shoulder pain?
- Dialysis danger: a new model aims to predict sudden blood pressure crashes
- A helping hand for dialysis: can coaching reduce the emotional toll?
- A simple blood pressure cuff trick could shield the heart in kidney disease
- Could cutting dialysis sessions in half improve life for seniors?
- Teaching dialysis patients to take control: can a Four-Week Nurse-Led program improve diet and Self-Care?